Nuclear Medicine Europe (formerly AIPES) is a European industrial association dedicated to the promotion, awareness, and advocacy of nuclear medicine and molecular healthcare in Europe. We are active in the fields of imaging and therapy using molecular and radioactive tracers. The primary objective of our association is to promote the economic and commercial interests of its members, particularly by raising awareness of the benefits of the products and services they provide.
In addition to this core activity, our association represents the common interests of its members in relations with European institutions, national and international authorities, and other scientific, educational, or professional associations and societies, such as EANM, EFPIA, CERN.
The Association does not interfere in the activities of its Members.
“Imaging & Therapy with Molecular and Radioactive Tracers”
Our Objectives:
Nuclear Medicine Europe’s position on radiopharmaceuticals is driven by three pillars:
Full compliance through adoption of all relevant requirements for both radioactivity and pharmaceuticals. Compliance covers the entire process, from research and development to manufacturing, distribution, and post-sale activities.
A tradition of innovation and commitment to novel tracers for the future. The development of new drugs will require a more tailored regulatory approach.
Ensuring the availability of products and technology for millions of nuclear medicine procedures across Europe, so that all patients have access to high-quality diagnostic and therapeutic care.
The General Assembly is composed of all members of the association. Each member appoints an authorized representative to attend and vote on its behalf at General Assembly meetings. The General Assembly adopts resolutions, elects association managers, and approves the admission of new members. Each representative has one vote, and resolutions are adopted only by unanimous consent.
Members may take decisions subject to General Assembly approval through written resolution by unanimous consent, without convening a meeting, except for decisions requiring notarial adoption. Following the adoption of any resolution, the Executive Committee ensures compliance with statutory filing requirements.
*Representatives are subject to change based on internal company decisions and delegation arrangements.
The sensitive nature of NMEU activities for the public, (i.e. human healthcare issues and radioactive hazards fear), implies at any time the risk of being the target of public inquiry and questioning. Moreover, NMEU wants to promote fair competition between its members. NMEU members should therefore at least fully comply with the EU and International legislation and principles related to:
President
Vice President and Secretary General
Vice President and Treasurer
Vice President
Vice President
Honorary President
The administration office, based in Brussels, serves as the central coordination hub for stakeholders across the nuclear medicine sector. It acts as a liaison office and information platform, facilitating communication and collaboration between the association and European institutions, regulatory bodies, industry partners, and other relevant entities.
Executive Administrator
